UNSPSC 51183500: Antidiabetic and hyperglycemic guanidines

This classification denotes iminourea derivatives based in whole or part on guanidine or CH5N3, substances called guanidines, that help regulate blood glucose levels, thus the term ANTIDIABETIC AND HYPERGLYCEMIC GUANIDINES.

UNSPSC 51183500 Antidiabetic and hyperglycemic guanidines is a Class code under which state and local governments procure generic pharmaceutical products, including antidiabetic agents and related drugs, through cooperative purchasing vehicles and direct state procurement channels. The work involves establishing supply contracts for pharmaceuticals distributed across state and local government facilities, clinics, and healthcare operations. Issuing bodies include state health departments and multistate cooperative purchasing alliances that bundle demand across multiple jurisdictions to negotiate volume pricing and standardized product specifications. State and local buyers source these products through established pharmaceutical wholesalers and require vendors to meet current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA approval, with detailed product coding and supply-chain documentation.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with response due March 26, 2026. This RFP covers participating state and local government facilities across Minnesota and Oregon, requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and evaluates proposals primarily on price competitiveness (75 percent weight) alongside fixed pricing, compliance with administrative data formats, EDI capability, and acceptance of a 3 percent administrative fee. Awarded vendors will be provided to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026 for an initial two-year term. The procurement reflects steady cooperative-purchasing activity in the upper Midwest, where multistate alliances consolidate pharmaceutical procurement to improve pricing and supply-chain efficiency across public health systems.